UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under
the Securities Exchange Act of 1934
(Amendment No. ________)*
ONCBIOMUNE PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
68235A 101
(CUSIP Number)
Andrew Kucharchuk
c/o OncBioMune Pharmaceuticals, Inc.
11441 Industriplex Blvd., Suite 190
Baton Rouge, LA 70809
(225) 227-2384
(Name,
Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
September 2, 2015
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ]
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 68235A 101 | 13D | Page 2 of 4 Pages |
| 1. | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
ANDREW KUCHARCHUK |
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ ] |
| 3. | SEC USE ONLY
|
| 4. | SOURCE OF FUNDS (see instructions)
OO |
| 5. | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] |
| 6. | CITIZENSHIP OR PLACE OF ORGANIZATION
UNITED STATES |
| NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7. | SOLE VOTING POWER
5,000,000 |
| 8. | SHARED VOTING POWER
0 | |
| 9. | SOLE DISPOSITIVE POWER
5,000,000 | |
| 10. | SHARED DISPOSITIVE POWER
0 |
| 11. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,000,000 |
| 12. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) [ ]
|
| 13. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.2%1 |
| 14. | TYPE OF REPORTING PERSON (see instructions)
IN |
1 This percentage is calculated based on 54,342,633 shares of common stock outstanding as of November 10, 2015.
| CUSIP No. 68235A 101 | 13D | Page 3 of 4 Pages |
Item 1. Security and Issuer.
This statement relates to the common stock of OncBioMune Pharmaceuticals, Inc. The issuer’s principal executive offices are located at 11441 Industriplex Blvd., Suite 190, Baton Rouge, LA 70809.
Item 2. Identity and Background.
(a) Andrew Kucharchuk
(b) Business Address: c/o OncBioMune Pharmaceuticals, Inc., 11441 Industriplex Blvd., Suite 190, Baton Rouge, LA 70809.
(c) The reporting person’s principal business is Chief Financial Officer and President of OncBioMune Pharmaceuticals, Inc.
(d) Criminal Proceedings: None
(e) Civil Proceedings: None
(f) Citizenship: United States
Item 3. Source or Amount of Funds or Other Consideration.
The reporting person acquired the shares in a grant from the Issuer on September 2, 2015.
Item 4. Purpose of Transaction.
The reporting person intends to participate in and influence the affairs of the Issuer as an officer and director of the Issuer and with respect to his voting rights associated with his shares of common stock. The reporting person’s voting power is 9.2%. Except as set forth herein, the reporting person does not have any present plans or proposals that relate to or would result in the occurrence of any of the events or matters described in Item 4(a)-(j) of Schedule 13D.
Item 5. Interest in Securities of the Issuer.
| (a) | The reporting person beneficially owns 5,000,000 shares of common stock, representing approximately 9.2% of the outstanding shares of common stock. The foregoing percentage is calculated based on 54,342,633 shares of common stock outstanding as of November 10, 2015. |
| (b) | The information set forth in Item 5(a) of this Schedule 13D is incorporated herein by reference. The reporting person has sole voting power and sole dispositive power over the shares of common stock, and does not have shared voting power or shared dispositive power over any shares of common stock. |
| (c) | The reporting person did not effect any transactions in the issuer’s common stock since July 4, 2015. |
| (d) | Other than the reporting person, no person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares that are the subject of this statement. |
| (e) | Not applicable. |
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
The information set forth under Items 3, 4 and 5 herein is incorporated herein by reference. The reporting person: (i) holds no options to purchase shares of common stock, (ii) has no interest in any other securities of the issuer, and (iii) is not a party to an agreement in which it shall receive additional securities of the issuer.
Item 7. Material to Be Filed as Exhibits.
None.
| CUSIP No. 68235A 101 | 13D | Page 4 of 4 Pages |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| Date: February 4, 2016 | |
| /s/ Andrew Kucharchuk | |
| Andrew Kucharchuk |